 |
市場調查報告書
商品編碼
1568884
PROTAC(蛋白質分解標的嵌合體)的全球市場:市場機會和臨床試驗趨勢(2027年)Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027 |
||||||
| 特徵 | 詳細內容 |
|---|---|
| 主要市場區隔 | 各適應症，各地區，技術各平台 |
| 治療領域 | 癌症，感染疾病，自體免疫·發炎性疾病，其他 |
| 觀察對象國家 | 美國，中國，韓國 |
| 報告目標範圍 | 作用機制，癌症的可能性，全面的臨床藥的洞察，目前趨勢與未來的機會 |
| 對象企業 | Arvinas，EnhancedBio，Uppthera，TYK Medicine，Axter Therapeutics等 |
蛋白水解靶向嵌合體 (PROTAC) 首次概念化於 2000 年代初，現已成為標靶治療的突破性方法。透過利用人體的天然泛素蛋白酶體系統，PROTAC 選擇性地去除與多種疾病相關的特定蛋白質，特別是那些歷來被認為無法治療的疾病。這種創新療法專注於解決複雜疾病患者治療方案的關鍵差距，並在學術和工業領域獲得關注。
PROTAC 透過一種獨特的機制發揮作用，該機制由三個基本成分組成：靶向配體、E3 連接酶配體和接頭。靶向配體特異性結合目標蛋白 (POIs)，這些蛋白質通常在疾病病理學中發揮重要作用。這包括與癌症和神經退化性疾病相關的蛋白質。 E3 連接酶配體將 PROTAC 連接到 E3 連接酶，E3 連接酶促進泛素分子與蛋白質的附著。當 PROTAC 同時與 POI 和 E3 連接酶結合時，PROTAC 催化泛素的轉移並標記蛋白酶體降解的目標。與傳統的小分子抑制劑相比，這種機制可以更有效、更精確地干預疾病過程，傳統的小分子抑制劑通常只抑制蛋白質功能而不促進降解。
PROTAC 最突出的應用是癌症治療。癌症涉及蛋白質之間的複雜相互作用，這些相互作用導致腫瘤生長、進展、轉移和對現有治療的抵抗。 PROTAC 已開發用於靶向和降解多種關鍵蛋白，包括 KRAS、BRAF、細胞週期蛋白依賴性激酶以及雌激素受體和雄激素受體等激素受體。在臨床試驗的候選藥物中，由Urvinus公司開發的雌激素受體降解藥物bepdegestrant（ARV-471）脫穎而出。截至2024年10月，Bepdegeslant正處於治療雌激素受體陽性、人類表皮生長因子受體2陰性（ER+/HER2-）乳癌的3期臨床試驗。這可能使其成為全球管道中最先進的 PROTAC 候選產品，並為其在本十年末成為第一個上市的 PROTAC 鋪平道路。
PROTAC 的商業前景正在快速成長，其特點是旨在加速基於 PROTAC 的新療法的發現和開發的策略研究合作。 2024 年 1 月，Galapagos 和 BridGene Biosciences 宣布開展策略合作，開發針對臨床驗證的腫瘤標靶的新型精準藥物。此次合作旨在利用兩家公司的專業知識並加強 PROTAC 的開發管道。 2024 年 8 月，兩家公司擴大了協議範圍，納入了在精準腫瘤學領域開發選擇性口服 SMARCA2 PROTAC 的努力，突顯了這一新領域的合作精神。
由於研究進展和藥物開發投資的增加，PROTAC 市場預計將顯著成長。 PROTAC 獨特的作用機制和針對以前無法治療的蛋白質的能力使 PROTAC 成為複雜疾病治療方法的一個有希望的補充。
本報告調查了全球 PROTAC（蛋白水解靶向嵌合體）市場，並提供了市場概況，包括藥物趨勢、臨床試驗趨勢、區域趨勢以及進入市場的公司的競爭格局。
目錄
第1章 PROTAC技術的簡介
第2章 PROTAC療法的癌症治療的可能性
- 作為標靶治療的重要性
- 與傳統治療方法的比較
第3章 PROTAC技術臨床概要
- PROTAC分子的成分
- 作用機制
第4章 全球PROTAC藥物市場趨勢的洞察
- 目前市場概要
- 未來臨床及商業機會
第5章 全球PROTAC藥物市場趨勢，各地區
- 美國
- 韓國
- 中國
第6章 世界PROTAC藥物臨床試驗概要
- 各企業
- 各國
- 患者各市場區隔
- 各相
- 依孤兒與快速通道狀態
第7章 全球PROTAC藥物臨床試驗的洞察:各企業，各國，各適應症，各相
- 調查
- 前臨床
- 第一階段
- 第一/二階段
- 第二階段
- 第三階段
第8章 全球PROTAC藥物市場趨勢，各適應症
- 癌症
- 感染疾病
- 神經退化性疾病
- 自體免疫疾病及發炎性疾病
- 心血管疾病
第9章 PROTAC技術平台
第10章 全球PROTAC藥物市場動態與展望
第11章 競爭情形
- Arvinas
- Axter Therapeutics
- Beactica
- BioTheryX
- EnhancedBio
- Suzhou Kintor Pharmaceuticals
- Monte Rosa Therapeutics
- TYK Medicine
- Ubix Therapeutics
- Uppthera
"Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027" Report Finding & Inclusions:
- First PROTAC Drug Approval Expected By 2027
- Global & Regional PROTAC Drug Market Trends Insight
- First 12 Months & First 5 Years Market Size Estimates Since Approval
- Global PROTAC Drugs Clinical Trials Insight By Company, Country, Indication & Phase: > 90 Drugs
- FDA Fast Track & Orphan Drug Status Insight By Company & Indication
- Comprehensive Insight On PROTAC Technology Platforms: 10 Platforms
- Global PROTAC Drug Market Trends By Indications
- Competitive Landscape
| Features | Details |
|---|---|
| Key Segments: | By Indication, By Region, Technology Platforms |
| Therapeutic Areas: | Cancer, Infectious Diseases, Autoimmune & Inflammatory Diseases and others |
| Countries Covered: | US, China, South Korea |
| Report Coverage | Mechanism of Action, Potential in Cancer, Comprehensive Clinical Drugs Insight, Current Trends and Future Opportunities |
| Companies Covered: | Arvinas, EnhancedBio, Uppthera, TYK Medicine, Axter Therapeutics among others |
First conceptualized in the early 2000s, proteolysis-targeting chimeras (PROTACs) are emerging as a transformative approach in targeted therapies. By harnessing the body's natural ubiquitin-proteasome system, PROTACs selectively eliminate specific proteins implicated in various diseases, particularly those that have been historically deemed undruggable. This innovative therapeutic modality is gaining traction in both academic and industrial settings, with a focus on addressing significant gaps in treatment options for patients with complex diseases.
PROTACs function through a unique mechanism that comprises three essential components: a targeting ligand, an E3 ligase ligand, and a linker. The targeting ligand binds specifically to the protein of interest (POI), which often plays a crucial role in disease pathology. This can include proteins associated with cancer or neurodegenerative disorders. The E3 ligase ligand links the PROTAC to an E3 ligase, an enzyme that facilitates the attachment of ubiquitin molecules to proteins. Once the PROTAC simultaneously binds to the POI and the E3 ligase, it catalyzes the transfer of ubiquitin, marking the target for degradation by the proteasome. This mechanism allows for a more effective and precise intervention in disease processes compared to traditional small molecule inhibitors, which often only inhibit protein function without promoting degradation.
The most prominent application of PROTACs is in cancer treatment. Cancer involves a complex interplay of proteins that contribute to tumor growth, progression, metastasis, and resistance to existing therapies. PROTACs are being developed to target and degrade a variety of key proteins, including KRAS, BRAF, cyclin-dependent kinases, and hormone receptors like estrogen and androgen receptors. Among the candidates in clinical trials, Vepdegestrant (ARV-471), an estrogen receptor degrader developed by Arvinas, stands out. As of October 2024, Vepdegestrant is undergoing phase 3 clinical trials for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. This makes it the most advanced PROTAC candidate in the global pipeline, potentially paving the way to become the first PROTAC on the market by the end of this decade.
In addition to Vepdegestrant, Arvinas is also conducting a Phase 1/2 clinical trial for Bavdegalutamide (ARV-110), a PROTAC targeting the androgen receptor in patients with metastatic castration-resistant prostate cancer. This dual approach highlights the potential of PROTACs to address multiple facets of cancer biology effectively.
Beyond oncology, the application of PROTACs is expanding into the realm of autoimmune and inflammatory disorders. Researchers are exploring their potential to degrade key proteins involved in inflammatory signaling pathways. Notably, proteins from the IRAK family, especially IRAK4, and BTK kinase are being targeted for PROTAC development in these areas. While most candidates in this category are still in early phases, with few like HSK-40118 and KT-474 currently in clinical trials, ongoing research promises to uncover more viable options in the future.
The commercial landscape for PROTACs is burgeoning, characterized by strategic collaborations aimed at accelerating the discovery and development of new PROTAC-based therapies. In January 2024, Galapagos and BridGene Biosciences announced a strategic partnership to develop novel precision medicines targeting clinically validated oncology targets. This collaboration aims to leverage both companies' expertise to enhance the development pipeline of PROTACs. In August 2024, they expanded their agreement to include efforts on developing a selective oral SMARCA2 PROTAC in precision oncology, underscoring the collaborative spirit in this emerging field.
The market for PROTACs is anticipated to grow significantly, driven by advancements in research and increasing investments in drug development. The unique mechanism of action and the ability to target previously undruggable proteins position PROTACs as a promising addition to the therapeutic arsenal against complex diseases.
As the PROTAC field continues to evolve, its clinical and commercial prospects look bright. The promising early results from clinical trials and the strategic partnerships being formed indicate that PROTACs could soon revolutionize treatment paradigms for various diseases, particularly cancer and autoimmune disorders. With ongoing research and development, PROTACs are set to become a cornerstone of targeted therapy, offering new hope to patients and filling critical gaps in treatment. As we move toward the latter half of this decade, the landscape of drug development is likely to be significantly reshaped by the success of PROTAC technology.
Table of Contents
1. Introduction To PROTAC Technology
- 1.1 Overview Of PROTAC Technology
- 1.2 Development & Evolution of PROTACs
2. PROTAC Therapies Potential In Cancer Therapeutics
- 2.1 Importance As Targeted Therapy
- 2.2 Comparison With Conventional Treatment Methods
3. Clinical Overview of PROTAC Technology
- 3.1 Components Of PROTAC Molecules
- 3.2 Mechanism Of Action
4. Global PROTAC Drug Market Trends Insight
- 4.1 Current Market Overview
- 4.2 Future Clinical & Commercial Opportunities
5. Global PROTAC Drug Market Trends By Region
- 5.1 US
- 5.2 South Korea
- 5.3 China
6. Global PROTAC Drugs Clinical Trials Insight Overview
- 6.1 By Company
- 6.2 By Country
- 6.3 By Patient Segment
- 6.4 By Phase
- 6.5 By Orphan & Fast Track Status
7. Global PROTAC Drugs Clinical Trials Insight By Company, Country, Indication & Phase
- 7.1 Research
- 7.2 Preclinical
- 7.3 Phase I
- 7.4 Phase I/II
- 7.5 Phase II
- 7.6 Phase III
8. Global PROTAC Drug Market Trends By Indication
- 8.1 Cancer
- 8.2 Infectious Diseases
- 8.3 Neurodegenerative diseases
- 8.4 Autoimmune & Inflammatory Diseases
- 8.5 Cardiovascular Diseases
9. PROTAC Technology Platforms
10. Global PROTAC Drugs Market Dynamics & Outlook
- 10.1 Drivers & Opportunities
- 10.2 Challenges & Restraints
11. Competitive Landscape
- 11.1 Arvinas
- 11.2 Axter Therapeutics
- 11.3 Beactica
- 11.4 BioTheryX
- 11.5 EnhancedBio
- 11.6 Suzhou Kintor Pharmaceuticals
- 11.7 Monte Rosa Therapeutics
- 11.8 TYK Medicine
- 11.9 Ubix Therapeutics
- 11.10 Uppthera
List of Figures
- Figure 1-1: PROTACs - Evolution Across Generations
- Figure 1-2: PROTACs - Major Developmental Milestones Over The Years
- Figure 2-1: PROTACs - Advantages As Cancer Target Therapy
- Figure 3-1: PROTAC - Typical Structure
- Figure 3-2: PROTACs - Mechanism Of Action
- Figure 4-1: Global - PROTA Therapy Market Size: First 12 Month & First 5 Years Since Approval, (US$ Million)
- Figure 6-1: Global - Number of PROTAC Drugs Clinical Trials By Company, 2024
- Figure 6-2: Global - Number Of PROTAC Drugs In Clinical Trials By Country, 2024
- Figure 6-3: Global - Number Of PROTAC Drugs In Clinical Trials By Patient Segment, 2024
- Figure 6-4: Global - Number Of PROTAC Drugs In Clinical Trials By Phase, 2024
- Figure 6-5: Global - Fast Track & Orphan Designated PROTAC Drugs In Clinical Trials, 2024
- Figure 8-1: Bavdegalutamide Phase I/II (NCT03888612) Study - Initiation & Completion Year
- Figure 8-2: Bavdegalutamide Phase I (NCT05177042) Study - Initiation & Completion Year
- Figure 8-3: Vepdegestrant Phase I/II (NCT04072952) Study - Initiation & Completion Year
- Figure 8-4: VERITAC-2 Phase III (NCT05654623) Study - Initiation & Completion Year
- Figure 8-5: VERITAC-3 Phase III (NCT05909397) Study - Initiation & Completion Year
- Figure 8-6: I-SPY-2 Phase II (NCT01042379) Study - Initiation & Completion Year
- Figure 8-7: ARV-393 Phase I (NCT06393738) Study - Initiation & Completion Year
- Figure 8-8: ADVANTA Phase II (NCT06058156) Study - Initiation & Completion Year
- Figure 8-9: ZEN Phase II (NCT06028230) Study - Initiation & Completion Year
- Figure 9-1: PROTAC(R) Discovery Engine - Arvinas
- Figure 9-2: Degraducer Technology - Ubix Therapeutics
- Figure 9-3: SpeedUPP Platform - UPPTHERA
- Figure 9-4: DaTProD Platform - HealZen Therapeutics
- Figure 10-1: Global PROTAC Drugs Market - Drivers & Opportunities
- Figure 10-2: Global PROTAC Drugs Market - Challenges & Restraints
List of Tables
- Table 2-1: Comparison of PROTACs With Conventional Therapies
- Table 6-1: Cancer - Clinical Trials Assessing ARV-471
